Management of glucocorticoid-induced osteoporosis
Long-term glucocorticoid (GC) therapy is frequently indicated to treat autoimmune and chronic inflammatory diseases in daily clinical practice. Two of the most devastating untoward effects are bone loss and fractures. Doses as low as 2.5 mg of prednisone for more than 3 months can impair bone integr...
Gespeichert in:
| Veröffentlicht in: | Aging clinical and experimental research 2021-04, Vol.33 (4), p.793-804 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 804 |
|---|---|
| container_issue | 4 |
| container_start_page | 793 |
| container_title | Aging clinical and experimental research |
| container_volume | 33 |
| creator | Messina, Osvaldo D. Vidal, Luis Fernando Wilman, Maritza Vidal Bultink, Irene E. M. Raterman, Hennie G. Lems, William |
| description | Long-term glucocorticoid (GC) therapy is frequently indicated to treat autoimmune and chronic inflammatory diseases in daily clinical practice. Two of the most devastating untoward effects are bone loss and fractures. Doses as low as 2.5 mg of prednisone for more than 3 months can impair bone integrity. Population at risk is defined based on the dose and duration of GC therapy and should be stratified according to FRAX (Fracture Risk Assessment Tool), major osteoporotic fracture, prior fractures, and bone mineral density values (BMD). General measures include to prescribe the lowest dose of GC to control the underlying disease for the shortest possible time, maintain adequate vitamin D levels and calcium intake, maintain mobility, and prescribe a bone acting agent in patients at high risk of fracture. These agents include oral and intravenous bisphosphonates, denosumab, and teriparatide. |
| doi_str_mv | 10.1007/s40520-021-01823-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2504352450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2504352450</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-166eba8cdfdd4aa22d6c34018a83a50ea7ec040e7c68745974d9c9a01506e19c3</originalsourceid><addsrcrecordid>eNp9kLtOwzAUhi0EoqXwAgyoEgtL4PgWJyNC3KQiFpgt1z6pUiVxsZOBt8cl5SIGJh_7fP59_BFySuGSAqirKEAyyIDRDGjBeAZ7ZEpVOio4Lfd_1RNyFOMaQNC0OSQTzpWkImdTQp9MZ1bYYtfPfTVfNYP11oe-tr52Wd25waKb-9ij3_jgYx2PyUFlmognu3VGXu9uX24essXz_ePN9SKzKbzPaJ7j0hTWVc4JYxhzueUizWkKbiSgUWhBACqbF0rIUglX2tIAlZAjLS2fkYsxdxP824Cx120dLTaN6dAPUTMJgksmJCT0_A-69kPo0nSJoqXMVcllothI2fSPGLDSm1C3JrxrCnorVI9CdRKqP4XqbfTZLnpYtui-r3wZTAAfgZha3QrDz9v_xH4Awy1_TA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2519567935</pqid></control><display><type>article</type><title>Management of glucocorticoid-induced osteoporosis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Messina, Osvaldo D. ; Vidal, Luis Fernando ; Wilman, Maritza Vidal ; Bultink, Irene E. M. ; Raterman, Hennie G. ; Lems, William</creator><creatorcontrib>Messina, Osvaldo D. ; Vidal, Luis Fernando ; Wilman, Maritza Vidal ; Bultink, Irene E. M. ; Raterman, Hennie G. ; Lems, William</creatorcontrib><description>Long-term glucocorticoid (GC) therapy is frequently indicated to treat autoimmune and chronic inflammatory diseases in daily clinical practice. Two of the most devastating untoward effects are bone loss and fractures. Doses as low as 2.5 mg of prednisone for more than 3 months can impair bone integrity. Population at risk is defined based on the dose and duration of GC therapy and should be stratified according to FRAX (Fracture Risk Assessment Tool), major osteoporotic fracture, prior fractures, and bone mineral density values (BMD). General measures include to prescribe the lowest dose of GC to control the underlying disease for the shortest possible time, maintain adequate vitamin D levels and calcium intake, maintain mobility, and prescribe a bone acting agent in patients at high risk of fracture. These agents include oral and intravenous bisphosphonates, denosumab, and teriparatide.</description><identifier>ISSN: 1720-8319</identifier><identifier>ISSN: 1594-0667</identifier><identifier>EISSN: 1720-8319</identifier><identifier>DOI: 10.1007/s40520-021-01823-0</identifier><identifier>PMID: 33751462</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Apoptosis ; Arthritis ; Bone Density ; Bone Density Conservation Agents - adverse effects ; Clinical medicine ; Disease ; Drug dosages ; Fractures ; Geriatrics/Gerontology ; Glucocorticoids - adverse effects ; Health risks ; Humans ; Medicine ; Medicine & Public Health ; Osteoporosis ; Osteoporosis - chemically induced ; Osteoporosis - drug therapy ; Osteoporotic Fractures - chemically induced ; Osteoporotic Fractures - prevention & control ; Pathogenesis ; Review ; Rheumatology ; Womens health</subject><ispartof>Aging clinical and experimental research, 2021-04, Vol.33 (4), p.793-804</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021. corrected publication 2021</rights><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021. corrected publication 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-166eba8cdfdd4aa22d6c34018a83a50ea7ec040e7c68745974d9c9a01506e19c3</citedby><cites>FETCH-LOGICAL-c375t-166eba8cdfdd4aa22d6c34018a83a50ea7ec040e7c68745974d9c9a01506e19c3</cites><orcidid>0000-0001-8494-5260</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40520-021-01823-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40520-021-01823-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33751462$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Messina, Osvaldo D.</creatorcontrib><creatorcontrib>Vidal, Luis Fernando</creatorcontrib><creatorcontrib>Wilman, Maritza Vidal</creatorcontrib><creatorcontrib>Bultink, Irene E. M.</creatorcontrib><creatorcontrib>Raterman, Hennie G.</creatorcontrib><creatorcontrib>Lems, William</creatorcontrib><title>Management of glucocorticoid-induced osteoporosis</title><title>Aging clinical and experimental research</title><addtitle>Aging Clin Exp Res</addtitle><addtitle>Aging Clin Exp Res</addtitle><description>Long-term glucocorticoid (GC) therapy is frequently indicated to treat autoimmune and chronic inflammatory diseases in daily clinical practice. Two of the most devastating untoward effects are bone loss and fractures. Doses as low as 2.5 mg of prednisone for more than 3 months can impair bone integrity. Population at risk is defined based on the dose and duration of GC therapy and should be stratified according to FRAX (Fracture Risk Assessment Tool), major osteoporotic fracture, prior fractures, and bone mineral density values (BMD). General measures include to prescribe the lowest dose of GC to control the underlying disease for the shortest possible time, maintain adequate vitamin D levels and calcium intake, maintain mobility, and prescribe a bone acting agent in patients at high risk of fracture. These agents include oral and intravenous bisphosphonates, denosumab, and teriparatide.</description><subject>Apoptosis</subject><subject>Arthritis</subject><subject>Bone Density</subject><subject>Bone Density Conservation Agents - adverse effects</subject><subject>Clinical medicine</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Fractures</subject><subject>Geriatrics/Gerontology</subject><subject>Glucocorticoids - adverse effects</subject><subject>Health risks</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Osteoporosis</subject><subject>Osteoporosis - chemically induced</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporotic Fractures - chemically induced</subject><subject>Osteoporotic Fractures - prevention & control</subject><subject>Pathogenesis</subject><subject>Review</subject><subject>Rheumatology</subject><subject>Womens health</subject><issn>1720-8319</issn><issn>1594-0667</issn><issn>1720-8319</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kLtOwzAUhi0EoqXwAgyoEgtL4PgWJyNC3KQiFpgt1z6pUiVxsZOBt8cl5SIGJh_7fP59_BFySuGSAqirKEAyyIDRDGjBeAZ7ZEpVOio4Lfd_1RNyFOMaQNC0OSQTzpWkImdTQp9MZ1bYYtfPfTVfNYP11oe-tr52Wd25waKb-9ij3_jgYx2PyUFlmognu3VGXu9uX24essXz_ePN9SKzKbzPaJ7j0hTWVc4JYxhzueUizWkKbiSgUWhBACqbF0rIUglX2tIAlZAjLS2fkYsxdxP824Cx120dLTaN6dAPUTMJgksmJCT0_A-69kPo0nSJoqXMVcllothI2fSPGLDSm1C3JrxrCnorVI9CdRKqP4XqbfTZLnpYtui-r3wZTAAfgZha3QrDz9v_xH4Awy1_TA</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Messina, Osvaldo D.</creator><creator>Vidal, Luis Fernando</creator><creator>Wilman, Maritza Vidal</creator><creator>Bultink, Irene E. M.</creator><creator>Raterman, Hennie G.</creator><creator>Lems, William</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8494-5260</orcidid></search><sort><creationdate>20210401</creationdate><title>Management of glucocorticoid-induced osteoporosis</title><author>Messina, Osvaldo D. ; Vidal, Luis Fernando ; Wilman, Maritza Vidal ; Bultink, Irene E. M. ; Raterman, Hennie G. ; Lems, William</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-166eba8cdfdd4aa22d6c34018a83a50ea7ec040e7c68745974d9c9a01506e19c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Apoptosis</topic><topic>Arthritis</topic><topic>Bone Density</topic><topic>Bone Density Conservation Agents - adverse effects</topic><topic>Clinical medicine</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Fractures</topic><topic>Geriatrics/Gerontology</topic><topic>Glucocorticoids - adverse effects</topic><topic>Health risks</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Osteoporosis</topic><topic>Osteoporosis - chemically induced</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporotic Fractures - chemically induced</topic><topic>Osteoporotic Fractures - prevention & control</topic><topic>Pathogenesis</topic><topic>Review</topic><topic>Rheumatology</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Messina, Osvaldo D.</creatorcontrib><creatorcontrib>Vidal, Luis Fernando</creatorcontrib><creatorcontrib>Wilman, Maritza Vidal</creatorcontrib><creatorcontrib>Bultink, Irene E. M.</creatorcontrib><creatorcontrib>Raterman, Hennie G.</creatorcontrib><creatorcontrib>Lems, William</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Aging clinical and experimental research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Messina, Osvaldo D.</au><au>Vidal, Luis Fernando</au><au>Wilman, Maritza Vidal</au><au>Bultink, Irene E. M.</au><au>Raterman, Hennie G.</au><au>Lems, William</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of glucocorticoid-induced osteoporosis</atitle><jtitle>Aging clinical and experimental research</jtitle><stitle>Aging Clin Exp Res</stitle><addtitle>Aging Clin Exp Res</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>33</volume><issue>4</issue><spage>793</spage><epage>804</epage><pages>793-804</pages><issn>1720-8319</issn><issn>1594-0667</issn><eissn>1720-8319</eissn><abstract>Long-term glucocorticoid (GC) therapy is frequently indicated to treat autoimmune and chronic inflammatory diseases in daily clinical practice. Two of the most devastating untoward effects are bone loss and fractures. Doses as low as 2.5 mg of prednisone for more than 3 months can impair bone integrity. Population at risk is defined based on the dose and duration of GC therapy and should be stratified according to FRAX (Fracture Risk Assessment Tool), major osteoporotic fracture, prior fractures, and bone mineral density values (BMD). General measures include to prescribe the lowest dose of GC to control the underlying disease for the shortest possible time, maintain adequate vitamin D levels and calcium intake, maintain mobility, and prescribe a bone acting agent in patients at high risk of fracture. These agents include oral and intravenous bisphosphonates, denosumab, and teriparatide.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>33751462</pmid><doi>10.1007/s40520-021-01823-0</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-8494-5260</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1720-8319 |
| ispartof | Aging clinical and experimental research, 2021-04, Vol.33 (4), p.793-804 |
| issn | 1720-8319 1594-0667 1720-8319 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2504352450 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Apoptosis Arthritis Bone Density Bone Density Conservation Agents - adverse effects Clinical medicine Disease Drug dosages Fractures Geriatrics/Gerontology Glucocorticoids - adverse effects Health risks Humans Medicine Medicine & Public Health Osteoporosis Osteoporosis - chemically induced Osteoporosis - drug therapy Osteoporotic Fractures - chemically induced Osteoporotic Fractures - prevention & control Pathogenesis Review Rheumatology Womens health |
| title | Management of glucocorticoid-induced osteoporosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T05%3A45%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20glucocorticoid-induced%20osteoporosis&rft.jtitle=Aging%20clinical%20and%20experimental%20research&rft.au=Messina,%20Osvaldo%20D.&rft.date=2021-04-01&rft.volume=33&rft.issue=4&rft.spage=793&rft.epage=804&rft.pages=793-804&rft.issn=1720-8319&rft.eissn=1720-8319&rft_id=info:doi/10.1007/s40520-021-01823-0&rft_dat=%3Cproquest_cross%3E2504352450%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2519567935&rft_id=info:pmid/33751462&rfr_iscdi=true |